Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age
Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®- (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement therapy for primary humoral immunodeficiency (PI) or secondary humoral immunodeficiency (SI) – to its list of plasma products distributed in Quebec.1The treatment will now be reimbursed for […]